UniProt: Q9C0D9 (EPT1_HUMAN). HGNC:29361. Human, NCBITaxon:9606. 397 aa.
Gene symbol SELENOI (synonyms EPT1, SELI, KIAA1724). All identifiers and quotes
below from file:human/SELENOI/SELENOI-uniprot.txt unless a PMID is given.
SELENOI is ethanolaminephosphotransferase 1 (EPT1 / hEPT1), a selenoprotein
(Selenoprotein I) and a multi-pass ER-membrane enzyme of the CDP-alcohol
phosphatidyltransferase class-I family. It catalyzes the final (third) step of
the CDP-ethanolamine branch of the Kennedy pathway for phosphatidylethanolamine
(PE) biosynthesis.
NON_STD 387 /note="Selenocysteine"),Two reactions in UniProt CATALYTIC ACTIVITY:
1. Diacyl (canonical PE): CDP-ethanolamine + 1,2-diacyl-sn-glycerol (DAG) =
1,2-diacyl-sn-glycero-3-phosphoethanolamine (PE) + CMP + H+ (RHEA:32943; EC 2.7.8.1),
evidenced experimentally by PubMed:17132865, 28052917, 29500230.
2. Ether-linked (plasmanyl-PE): 1-O-alkyl-2-acyl-sn-glycerol + CDP-ethanolamine =
1-O-alkyl-2-acyl-sn-glycero-3-phosphoethanolamine + CMP + H+ (RHEA:36187),
ECO:0000305 from PubMed:29500230.
Cofactor: Mg(2+) or Mn(2+) (ECO:0000269|PubMed:17132865). Kinetics: KM 1.8 uM for
CDP-ethanolamine (PubMed:17132865). Explains the metal ion binding (GO:0046872,
UniProtKB-KW) IEA annotation, though this is over-annotation of the divalent-cation
requirement rather than a distinct informative MF.
PATHWAY: "Phospholipid metabolism; phosphatidylethanolamine biosynthesis;
phosphatidylethanolamine from ethanolamine: step 3/3"
[file:human/SELENOI/SELENOI-uniprot.txt "phosphatidylethanolamine from ethanolamine: step 3/3"].
PMID:17132865 (Horibata & Hirabayashi 2007, J Lipid Res) — abstract-only cache
(full_text_available: false). Identified/characterized hEPT1: bacterial (E. coli)
expression showed the product "specifically used CDP-ethanolamine as the phosphobase
donor to produce PE with the activation by both Mn(2+) and Mg(2+)"
PMID:17132865.
Supports GO:0004307 (IDA, HGNC) and GO:0006646 (IDA). CDP-alcohol phosphatidyltransferase
signature noted PMID:17132865.
Tissue specificity: ubiquitous; highest in brain cerebellum.
PMID:28052917 (Ahmed et al. 2017, Brain) — FULL TEXT available. First human disease
(complex HSP / SPG81) from EPT1 mutation; p.Arg112Pro in the CDP-alcohol phosphotransferase
motif. WT and mutant human EPT1 expressed in an S. cerevisiae strain "devoid of endogenous
ethanolaminephosphotransferase activity"; 14C-ethanolamine incorporation into PE by the
mutant was "only 3% that of wild-type EPT1" — a loss-of-function
PMID:28052917. Supports IMP GO:0004307 & GO:0006646.
ER-membrane / integral-membrane: the enzyme was "associated with the membrane fraction as
would be expected for an integral membrane protein"
PMID:28052917.
NOTE: the "is_active_in ER membrane" IDA (ECO:0000314, PubMed:28052917) rests on membrane-
fraction association in the heterologous yeast system, not on direct human-cell imaging;
the ER localization is nonetheless firmly established across sources (UniProt SUBCELLULAR
LOCATION, Reactome). Kept as core location.
Function: "catalyses the final step in the synthesis of PE via the Kennedy pathway"
PMID:28052917.
PMID:29500230 (Horibata et al. 2018, J Lipid Res) — abstract-only cache. Patient with
severe complicated HSP; EPT1 exon-skipping mutation. EPT "transfers phosphoethanolamine
from cytidine diphosphate-ethanolamine to lipid acceptors to produce ethanolamine
glycerophospholipids, such as diacyl-linked phosphatidylethanolamine (PE) and ether-linked
plasmalogen [plasmenyl-PE]"
PMID:29500230.
In patient fibroblasts and EPT1-KO HeLa cells: reduced PE species and "most plasmenyl-PE
species were significantly decreased" PMID:29500230.
Concludes "the indispensable role of EPT1 in the myelination process and neurodevelopment,
and in the maintenance of normal homeostasis of ether-linked phospholipids in humans"
PMID:29500230.
Supports IMP GO:0004307 & GO:0006646; underpins ISS/Ensembl myelination (GO:0042552) and
ether-lipid (GO:0008611) annotations.
Spastic paraplegia 81, autosomal recessive (SPG81; MIM:618768) — a complicated HSP with
white-matter abnormalities / hypomyelination, delayed motor development, spasticity, impaired
intellectual development, bifid uvula, microcephaly, seizures, ocular anomalies
[file:human/SELENOI/SELENOI-uniprot.txt "Spastic paraplegia 81, autosomal recessive (SPG81)"].
Refs: PubMed:28052917, 29500230, 36942482. This is a phenotypic/disease association, not a GO
process the gene product directly executes; myelination (GO:0042552) is the closest BP but is
downstream/consequential and only IEA/ISS-supported → KEEP_AS_NON_CORE.
Core MF: GO:0004307 ethanolaminephosphotransferase activity (IDA PMID:17132865, IMP
PMID:28052917, IMP PMID:29500230; also IBA/ISS/IEA). ACCEPT the experimental ones as core.
Core BP: GO:0006646 phosphatidylethanolamine biosynthetic process (IDA/IMP experimental).
ACCEPT as core (this is the specific "PE from CDP-ethanolamine, step 3/3" pathway; no
more-specific GO child exists — verified against go.db).
Core CC: GO:0005789 endoplasmic reticulum membrane (IDA PMID:28052917; IBA; IEA; TAS
Reactome). ACCEPT as core location.